Now, it was proved: ten days after vaccination, none of the trial subjects developed Ebola virus disease. When a new case of Ebola was diagnosed, the teams offered vaccination to everybody who had been in contact with that person in the previous three weeks, from family to friends and neighbors. Even babies received vaccination. There were very few serious side-effects – one case of fever and one of anaphylaxis (allergic reaction) thought to be related to the vaccine. Merck, Sharp & Dohme, the company manufacturing the vaccine, has received permission to go through fast-track procedures for a license from the US and European regulatory authorities. 300,000 doses will be ready for any emergency even before formal approval.